Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald N Jones

Showing results (21-30 of 662) with videos related to

Pageof 67
Sort By:
Diagnostic Microbiology and Infectious Disease|May 1, 2020
Reanalysis of cefazolin surrogate susceptibility breakpoints utilized as guidances for oral cephalosporin treatments of uncomplicated urinary tract infections: caution concerning application to cefadroxilHien M Nguyen, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|January 25, 2003
Antimicrobial activity of broad-spectrum agents tested against Gram-negative bacilli resistant to ceftazidime: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001)Ronald N Jones, David J Varnam
The Journal of Antimicrobial Chemotherapy|December 21, 2002
Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitorRonald N Jones, Paul R Rhomberg
International Journal of Antimicrobial Agents|June 7, 2003
Initial disk diffusion quality control guidelines for tylosin tested against Staphylococcus aureus ATCC 25923 and Streptococcus pneumoniae ATCC 49619Tamara R Anderegg, Ronald N Jones,
Diagnostic Microbiology and Infectious Disease|February 6, 2004
Disk diffusion quality control guidelines for NVP-PDF 713: a novel peptide deformylase inhibitorTamara R Anderegg, Ronald N Jones,
International Journal of Antimicrobial Agents|January 25, 2005
Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilliHelio S Sader, Ronald N Jones
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 1, 1997
CQ-397 and CQ-414: antimicrobial activity and spectrum of two fluoroquinolone---cephalosporin, dual-action compounds with carboxamido bondsDavid M. Johnson, Ronald N. Jones
Diagnostic Microbiology and Infectious Disease|February 23, 2002
In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinumPaul R Rhomberg, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|May 22, 2012
Antimicrobial activity of daptomycin in comparison to glycopeptides and other antimicrobials when tested against numerous species of coagulase-negative StaphylococcusHelio S Sader, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|April 4, 2002
Ciprofloxacin as broad-spectrum empiric therapy--are fluoroquinolones still viable monotherapeutic agents compared with beta-lactams: data from the MYSTIC Program (US)?Ronald N Jones, Michael A Pfaller
Pageof 67

Showing results (21-30 of 662) with videos related to

Sort By:
Pageof 67
Diagnostic Microbiology and Infectious Disease|May 1, 2020
Reanalysis of cefazolin surrogate susceptibility breakpoints utilized as guidances for oral cephalosporin treatments of uncomplicated urinary tract infections: caution concerning application to cefadroxilHien M Nguyen, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|January 25, 2003
Antimicrobial activity of broad-spectrum agents tested against Gram-negative bacilli resistant to ceftazidime: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001)Ronald N Jones, David J Varnam
The Journal of Antimicrobial Chemotherapy|December 21, 2002
Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitorRonald N Jones, Paul R Rhomberg
International Journal of Antimicrobial Agents|June 7, 2003
Initial disk diffusion quality control guidelines for tylosin tested against Staphylococcus aureus ATCC 25923 and Streptococcus pneumoniae ATCC 49619Tamara R Anderegg, Ronald N Jones,
Diagnostic Microbiology and Infectious Disease|February 6, 2004
Disk diffusion quality control guidelines for NVP-PDF 713: a novel peptide deformylase inhibitorTamara R Anderegg, Ronald N Jones,
International Journal of Antimicrobial Agents|January 25, 2005
Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilliHelio S Sader, Ronald N Jones
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 1, 1997
CQ-397 and CQ-414: antimicrobial activity and spectrum of two fluoroquinolone---cephalosporin, dual-action compounds with carboxamido bondsDavid M. Johnson, Ronald N. Jones
Diagnostic Microbiology and Infectious Disease|February 23, 2002
In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinumPaul R Rhomberg, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|May 22, 2012
Antimicrobial activity of daptomycin in comparison to glycopeptides and other antimicrobials when tested against numerous species of coagulase-negative StaphylococcusHelio S Sader, Ronald N Jones
Diagnostic Microbiology and Infectious Disease|April 4, 2002
Ciprofloxacin as broad-spectrum empiric therapy--are fluoroquinolones still viable monotherapeutic agents compared with beta-lactams: data from the MYSTIC Program (US)?Ronald N Jones, Michael A Pfaller
Pageof 67